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HSV-1716 is a replication-restricted, neuroattenuated ICP 34.5 gene mutant of herpes simplex virus type 1 (HSV-1).
Because of the attenuated phenotype of ICP 34.5 mutants in rodent models of HSV disease, they have been promoted as
potential vaccine strains and gene therapy vectors and have been used by us and others as therapeutic agents for the
treatment of experimental malignant tumors. However, all data on the phenotype of HSV-1716 and other ICP 34.5 mutants
are from animal model systems, while humans are the natural hosts of HSV-1. To achieve an initial characterization of the
phenotype of 1716 in human tissue, we have studied its replication in mature human skin xenografts on SCID mice. We
find that replication of 1716 is severely restricted in such human skin grafts relative to both parental wild-type HSV-1 strain
17/ and the HSV-1716 revertant virus 1716R, in which the 759-bp ICP 34.5 gene deletions have been repaired. Moreover,
the replication of both 1716 and 17/ is significantly better in the human skin grafts than it is in mouse skin. The implications
of these findings are discussed. q 1996 Academic Press, Inc.
HSV-1716 has a 759-bp deletion in both copies of the therapeutic agents for treatment of brain tumors, has
prompted us to explore the in vivo phenotype of 1716 inICP 34.5 gene (1). Deletion or mutation of the ICP 34.5
more detail. Human skin xenograft systems have beengene results in HSV-1 variants that are incapable of repli-
employed to achieve replication of varicella zoster virus,cating in the central nervous system of mice and do not
human papilloma virus, and molluscum contagiosum vi-cause encephalitis when inoculated via various routes
rus, which are fastidious human dermatotrophic viruses(1– 3). This is in sharp contrast to wild-type HSV-1, which
(11 – 13). In the case of HSV-1, the use of a human skingrows exponentially in brain and kills mice within days
xenograft system allows for studies in a prototypic hu-of inoculation (1).
man tissue of natural acute infection.In vitro, ICP 34.5 HSV-1 mutants grow as well as wild-
We find that the replication of both HSV-1716 and wild-type virus on dividing cells of most established cell lines
type HSV-17/ is much more efficient in the human skin(1, 2, 4). However, on nondividing cells such as confluent
than it is in mouse skin. Moreover, we find that relativeprimary mouse embryo cells, these mutants show im-
to wild-type HSV-17/, and the revertant virus HSV-1716R,paired replication (4). In previous studies, we, and others,
the replication of HSV-1716 is severely restricted in hu-have examined the replicative phenotype of ICP 34.5
man skin xenografts in vivo.HSV-1 mutants in vivo in nonneuronal tissues in mice.
The titration data shown in Fig. 1 demonstrate theThese mutant viruses showed limited replication in the
restricted nature of HSV-1716 in the human skin xeno-footpad (5), and replication in the eye could not be dem-
grafts relative to wild-type HSV-17/ and the revertantonstrated following intraocular inoculation (6, 7).
virus HSV-1716R. HSV 1716 shows only a slow increaseWe have recently shown that 1716 induced regression
in titer over the 3 days examined. In contrast, HSV-17/of preformed experimental intracranial melanoma and
demonstrates exponential growth in the human skin oversignificantly improved survival times of treated tumor
the same time period. To confirm that the phenotype ofbearing mice (8). Similar results with other types of brain
1716 in the human skin was attributable to deletion of
tumors have been demonstrated by others using compa- the ICP 34.5 gene, and not an additional unknown muta-
rable HSV-1 ICP 34.5 mutants (9, 10). The exciting poten- tion, we also examined the replication of a revertant vi-
tial of HSV-1 ICP 34.5 mutants as vaccine strains, and rus —1716R— in which the 759-bp ICP 34.5 gene dele-
tions have been repaired (14). As shown in Fig. 1, 1716R
demonstrated brisk replication in the human skin grafts1 To whom reprint requests should be addressed.
and thus has a phenotype like that of wild-type 17/.
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FIG. 1. Replication of HSV 17, 1716R, and 1716 in mouse skin and mature human skin xenografts. Full-thickness human foreskin xenografts were
produced on SCID mice as previously described (17). Defatted full-thickness human skin grafts, 1.5 cm in diameter, consisting of neonatal foreskin
from elective circumcision, were grafted onto the flank of mice after removing full-thickness skin at the recipient site down to fascia. The grafts
were sewn on, covered with an adhesive bandage clipped to the mouse, and covered with cloth tape. The grafts were left undisturbed until they
had matured for 4 –6 weeks. For inoculation directly into mouse skin, an 5-cm2-area patch of hair was removed from one flank using a chemical
depilatory agent 1 day prior to viral inoculation (Magic Shaving Powder, Carson Products Co., Savannah GA). Mice were anesthetized with im
ketamine/xylazine, and 5 1 106 PFU of HSV 17/, 1716R, or 1716, in a total volume of 50 ml, were injected intracutaneously into either their flank
skin or within mature human skin xenografts using a Hamilton syringe and a disposable 30-gauge needle. At the various times shown, mice were
sacrificed by lethal injection of anesthesia, and the entire xenograft, or the 5-cm2 patch of mouse flank skin surrounding the site of inoculation,
was removed aseptically to the level of fascia and frozen in liquid nitrogen. At the time of viral titration assay, each tissue sample was rapidly
thawed in a 377 water bath, and the tissue was homogenized in viral culture medium at a 10% weight/volume ratio using a Pyrex Ten Broeck tissue
grinder. The homogenates were centrifuged at 3000 g for 10 min at 47. The supernatant of each tissue homogenate was diluted logarithmically in
media, and the viral titer of each was determined in triplicate by plaque assay on BHK cells (18). Each data point represents the mean { standard
error of two tissue samples, and the experiment shown was repeated with similar results.
Comparison of the replication of 1716 and 17/ virus In fact, the sections shown in Fig. 2 for 1716 were se-
lected specifically to show evidence of 1716-induced pa-in the human skin xenografts to that in SCID mouse skin
demonstrates that both viruses replicate much better in thology. The majority of tissue sections of 1716-infected
human skin xenografts examined did not show any histo-the human skin. As shown in Fig. 1 intracutaneous inocu-
lation of SCID mouse flank skin resulted in a level of pathologic or immunohistochemical evidence of HSV in-
fection.replication of both 1716 and 17/ that was just at the
threshold of our titration assay. Despite a continual drop In contrast to HSV-1716, wild-type 17/ showed gross,
histopathologic, and immunohistochemical evidence ofin titer over the 3 days examined, we believe that the
rather slow decline most likely represents low-level repli- robust replication and pathologic effects. By Day 3 post-
inoculation focal epidermal histopathologic and immuno-cation rather than a complete absence of replication.
The restricted nature of HSV-1716 replication relative histochemical effects attributable to HSV were clearly
seen. By Day 7 postinoculation with 17/, near total de-to that of wild-type 17/ in the human skin xenografts is
further supported by gross and histologic examinations struction of the human skin grafts was seen. As is evident
in the representative gross photograph in Fig. 2, full thick-of the tissues at various times postinfection. Hematoxylin
and eosin sections are paired with sections stained im- ness epidermal ulceration is present in the majority of
the xenograft. The representative histologic section frommunohistochemically for HSV-1 antigens. HSV cytopathic
effect and antigen staining within the human skin xeno- Day 7 post 17/ infection shows complete loss of the
epidermis with necrotic crust present. Immunohisto-grafts subsequent to HSV-1716 infection were scant, fo-
cal, and restricted to the epidermis at all times examined. chemical evaluation shows HSV antigen staining at the
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FIG. 2. Comparison of the gross and histologic changes caused by HSV-17 and 1716 in mature human skin xenografts. Full-thickness human foreskin
xenografts were produced on SCID mice as described in the legend to Fig. 1. Mice were anesthetized with im ketamine/xylazine, and 5 1 106 PFU of
HSV 17/ or 1716, in a total volume of 50 ml, were injected intracutaneously within mature human skin xenografts using a Hamilton syringe and a disposable
30-gauge needle. At the various times shown, mice were sacrificed by lethal injection of anesthesia, and the entire xenograft was removed aseptically to
the level of fascia and fixed in 10% neutral buffered Formalin. Histologic sections for light microscopy were stained with hematoxylin and eosin. Parallel
sections were stained for HSV antigen expression using an indirect avidin–biotin immunoperoxidase method (Vector Labs, Burlingam, CA) as specified
by the manufacturer with slight modifications developed in our laboratory (19). Rabbit antiserum to HSV-1 (Dako Corp., Carpinteria, CA) was used at a
dilution of 1:1000. Sections were counterstained with hematoxylin. As a control for the specificity of immunostaining, nonimmune rabbit serum was substituted
for the primary HSV-1 antiserum (data not shown). Magnification is 2001 in all histologic sections.
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edge of the xenograft and staining of adnexal structures tissue such as preinjection of the footpad with hypertonic
saline, abrasion of the footpad or lip with an emery board,within the dermis. By Day 10 post 17/ infection, all sec-
tions examined exhibited complete epidermal destruc- scarification of the cornea with a needle, or abrasion
of the vaginal mucosa with a cotton applicator stick istion and significant dermal adnexal infection by immuno-
histochemistry. necessary to successfully inoculate virus at peripheral
sites (6, 7, 16). For the purpose of this study a relativelyWhen HSV-1716 or HSV-17/ was inoculated into depili-
tated mouse skin, no gross alteration was seen sur- nontraumatic intracutaneous injection was used. Al-
though this is clearly sufficient to establish an ongoingrounding the site (data not shown).
This study provides initial information on the pheno- infection in the human skin xenografts, it is apparently
not sufficient to do so in murine flank skin in the casetype of the HSV-1 ICP 34.5 mutant 1716 in human tissue.
Although the restricted nature of the replication of this of 17/. We are presently investigating the phenotype of
other ‘‘wild-type’’ clinical isolates and mutants in humanvirus in neuronal tissues is well established (1, 2, 4), the
replication of this and other ICP 34.5 mutants in nonneu- skin xenografts.
While the dramatic difference in replication betweenronal tissues is less well documented. A study examining
the replication of 1716 in mouse footpad found that the 1716 and 17/ in the human xenograft skin offers encour-
agement as to the attenuated nature of ICP 34.5 HSV-1peak viral titer on Day 1 postinfection was comparable
to that of wild type, but that the duration of recovery of mutants in nonneuronal human tissues, the impressive
differences in replication found between the human andtiterable virus was several days shorter for the mutant
(5). The peak vaginal viral titer of an HSV-1 strain F ICP mouse skin for both mutant and wild-type HSV offer yet
another reminder that the mouse is a far from perfect34.5 mutant was shown to be approximately 100-fold less
than that of wild type on average over Days 1 to 8 post model for study of a human pathogen such as HSV-1.
intravaginal infection in mice and guinea pigs (7). No
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